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C L I N I C A L C O M M E N T A R Y
What is the best test 
to detect herpes in skin lesions?
Test ulcers with culture or PCR
Genital and oral lesions consistent with herpes
simplex lesions are relatively common in my
practice. Before PCR testing was available, ulcers
could be tested via culture—which took too long
to be immediately useful—or via Tzanck smear,
which helped greatly if multinucleated giant cells
were seen. However, both tests were relatively
insensitive. As this Clinical Inquiry demonstrates,
ulcers currently should be tested either with cul-
ture or with PCR. Herpes culture is most sensitive
if vesicles are still intact for unroofing.
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Polymerase chain reaction (PCR) techniques
appear to be more sensitive and specific in detect-
ing herpes simplex virus (HSV) in genital lesions
(strength of recommendation [SOR]: A, based on 2
diagnostic cohort studies); however, viral culture
remains the gold standard (SOR: C, based on
expert opinion). Studies of serologic and antibody
detection tests report higher sensitivities than viral
culture (SOR: C, based on consensus guidelines).
Cytologic tests such as the Tzanck smear and
Papanicolaou (Pap) smear have poor sensitivities
and specificities and should not be relied upon for
a diagnosis of genital herpes (SOR: C, based on
expert opinion). 
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■ Evidence summary
More than 50 million individuals in the
United States have genital herpes. The
diagnosis of genital herpes based on clini-
cal history and physical examination is
often inaccurate.1 Clinical suspicion needs
to be confirmed by laboratory testing
because it has a direct impact on counsel-
ing and prognosis.2
Viral culture is still the gold standard
test for the detection of HSV; however, the
rate of positive cultures depends on the
stage of the lesion, the quality of the spec-
imen, and the transport conditions. A
British study3 found the rate of virus recov-
ery for early vesicles to be 52% to 93%.
This dropped to 41% to 72% if midstage
ulcers were present. Finally, the detection
for late-stage crusted lesions was only 19%
to 27%. Another disadvantage is that cul-
ture is labor-intensive. A positive culture
takes an average of 3 days to grow, where-
as a negative culture must incubate for 
10 days.3
PCR techniques are more sensitive and
results can be available in less than 4
hours.3 In 110 clinical samples from der-
mal or genital lesions of patients with sus-
pected HSV infection, the sensitivity of
PCR was 98% (positive likelihood ratio
[LR+] = ∞; negative likelihood ratio [LR–]
= 0.02) compared with 73% (LR+ = ∞;
LR– = 0.27) for culture. The specificities of
both were 100%.4 In London, 233 samples
from patients at a genitourinary medicine
clinic were tested with both viral culture
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Viral culture is
still the gold 
standard, but PCR
is more sensitive
and faster (and
may be less
expensive due to
decreased labor
costs)
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and PCR. HSV was detected in 79 samples
by culture and 132 samples by PCR. The
detection by PCR was higher in early as
well as late stages of infection and in both
first and recurrent episodes.3 The reference
standard for these studies was not an inde-
pendent standard, but a positive result on
both tests or modified versions of the PCR
test. The use of a version of the test of inter-
est (PCR) as part of the reference standard,
while probably unavoidable in this situa-
tion, will tend inflate the sensitivity and
specificity.
In another study, daily sampling of
lesions in patients with known HSV infec-
tions detected HSV DNA on 15 of 17 days
with PCR and only 3 of 17 days with cul-
ture.1 This suggests that PCR is more effec-
tive in detecting early, as well as late, stages
of infection. Currently PCR is more expen-
sive, but it may become cheaper because of
decreased labor expense when compared
with culture.
Genital herpes may also be detected
with enzyme immunoassay testing in as lit-
tle as 5 hours. In a study5 using 275 sam-
ples from genital lesions, HSV was detect-
ed in 65% of the antigen tests and 53% of
the viral cultures. The sensitivity of this
method is equal to culture for early lesions,
but much higher in late-stage lesions (58%
vs 26%).5
Serologic tests are often used to detect
HSV because they can differentiate
between HSV-1 and HSV-2. There is an
FDA-approved point-of-care test called
POCkit that gives results from capillary
blood or serum during an office visit. These
tests are 80% to 98% sensitive and more
than 96% specific. Unfortunately, they are
not readily available in all countries.2
Other detection methods include the
Tzanck smear, which is only 40% to 50%
sensitive compared with culture, and the
Pap smear, which is 60% to 70% sensitive.6
These tests should not be the sole method
for the diagnosis of HSV. They cannot 
differentiate between HSV 1 and HSV 2;
furthermore, the Tzanck prep will give a
positive result if varicella zoster virus is
present.6 If these tests are positive, confir-
matory testing specific for HSV should be
performed.
Recommendations from Others
The Centers for Disease Control and
Prevention7 recommends screening with a
viral culture when a genital lesion is pres-
ent, however, the sensitivity declines rapid-
ly within a few days as the lesion begins to
heal. To collect a sample the lesion must be
unroofed using a Dacron swab, which is
then placed in a viral transport medium
and processed within 24 hours. Swabs con-
taining calcium agglutinate are toxic to
HSV.6 Type-specific antibodies develop
during the first several weeks and can be
detected with serologic tests; however,
these may be falsely negative in the early
stages of a primary infection.7
The US Preventative Services Task
Force8 recommends against routine sero-
logic screening for HSV in asymptomatic
adolescents and adults. They also recom-
mend against routine screening of asymp-
tomatic pregnant women at any time dur-
ing pregnancy as a way to decrease neona-
tal transmission.8
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